Brokers Issue Forecasts for CG Oncology, Inc.’s Q1 2025 Earnings (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of CG Oncology in a report released on Friday, August 9th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for CG Oncology’s Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.51) EPS.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million during the quarter.

CGON has been the topic of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. The Goldman Sachs Group upgraded shares of CG Oncology from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $43.00 to $50.00 in a research note on Monday, May 13th. Finally, Bank of America began coverage on CG Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $65.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, CG Oncology has a consensus rating of “Buy” and a consensus price target of $64.00.

CG Oncology Trading Down 2.2 %

Shares of NASDAQ:CGON opened at $32.90 on Monday. CG Oncology has a 1 year low of $25.77 and a 1 year high of $50.23. The firm’s 50-day moving average is $33.39 and its two-hundred day moving average is $36.44.

Hedge Funds Weigh In On CG Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of CG Oncology during the 1st quarter worth approximately $102,000. California State Teachers Retirement System acquired a new stake in CG Oncology during the 1st quarter worth $103,000. Rhumbline Advisers lifted its position in CG Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 34,229 shares of the company’s stock valued at $1,081,000 after acquiring an additional 3,940 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of CG Oncology by 2.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 266,787 shares of the company’s stock worth $8,422,000 after purchasing an additional 6,899 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of CG Oncology during the first quarter worth about $492,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.